Cannabis and Klotho: What the 2026 Biological Aging Study Really Says

Why a biomarker headline deserves a sober read

In January 2026, Journal of Cannabis Research published a nationally representative analysis suggesting that frequent cannabis use is associated with lower circulating Klotho — a protein increasingly used by researchers as a proxy for biological aging. The paper did not prove that cannabis makes you age faster. It did find a statistically significant inverse association in a large middle-aged sample, and a second independent NHANES analysis, published a few months earlier in Tobacco Induced Diseases, reported the same direction of effect even after adjusting for tobacco.

That is worth taking seriously, and worth taking calmly. Biomarker studies are early signals, not verdicts. The point of this breakdown is to walk through what the research actually measured, what it did and did not control for, and what — if anything — a thoughtful consumer should do with it.

What Klotho actually is (and why researchers care)

Klotho is a protein — primarily produced in the kidneys and choroid plexus of the brain — first identified in 1997 by Makoto Kuro-o at the National Institute of Neuroscience in Japan. Mice genetically engineered to produce less Klotho developed a syndrome resembling accelerated aging: arteriosclerosis, osteoporosis, cognitive decline, and shortened lifespan. Mice that overexpressed Klotho lived measurably longer. That’s the foundational reason the protein earned the nickname “anti-aging.”

In humans, Klotho shows up in the bloodstream as serum α-Klotho and can be measured by ELISA from a standard blood draw. Lower circulating α-Klotho in adults has been associated in observational research with higher cardiovascular mortality, more severe age-related cognitive decline, reduced kidney function, and increased all-cause mortality. That’s why NHANES — the CDC’s nationally representative health survey — measured α-Klotho in roughly 13,000 adults aged 40 to 79 between 2007 and 2016, and why dozens of follow-up papers have used that dataset to ask which lifestyle factors correlate with it.

Klotho is not a perfect aging clock. It reflects one slice of physiology — largely tied to phosphate handling, FGF23 signaling, oxidative stress, and endothelial function — and people with similar Klotho levels can differ dramatically in their actual health trajectories. But across populations, lower levels track with poorer outcomes, and that makes it a reasonable (if imperfect) marker to study. For broader context on how cannabis interacts with the body’s signaling systems, our endocannabinoid system guide is a good companion read.

What the 2026 paper found, in plain language

Wang and colleagues analyzed NHANES data from 5,827 U.S. adults aged 40–59 years surveyed between 2007 and 2016. Cannabis use was self-reported and grouped into never, former, occasional, and frequent categories. Serum α-Klotho was measured at the CDC lab.

After adjusting for age, sex, race/ethnicity, income, education, body mass index, physical activity, alcohol, tobacco, and several medical conditions, the researchers reported:

• Frequent cannabis users had Klotho levels about 57.94 pg/mL lower than never-users, with a p-value of 0.027. In a population whose median Klotho sits near 800 pg/mL, that is a roughly 7 percent lower average.
• A dose-dependent trend across use categories was significant at p = 0.022, meaning the more frequent the use, the lower the Klotho on average.
• The association persisted in non-smokers (p = 0.047), suggesting the finding is not simply a proxy for tobacco co-use.
• The E-value was 4.77, which is a sensitivity statistic researchers use to ask how strong an unmeasured confounder would need to be to explain away the result. An E-value that size means a hidden variable would have to be roughly as predictive of Klotho as smoking is of lung cancer — a high bar, though not an impossible one.

The authors are careful in their own abstract: they call the finding “an association” and explicitly do not claim that cannabis causes lower Klotho. That restraint is the right tone, and it’s the tone this article will hold.

Methodology: strengths and caveats

NHANES is, for epidemiology purposes, one of the best datasets in the world. It uses complex survey weighting so results generalize to the civilian non-institutionalized U.S. population, biospecimens are processed under CDC lab protocols, and the sample size — nearly 6,000 adults with measured Klotho and detailed cannabis questions — is large enough to detect modest effects.

That said, there are real limits:

• Cross-sectional design. The survey measured Klotho and cannabis use at the same point in time. That means direction of effect cannot be established. It is possible that people with lower Klotho (for reasons entirely unrelated to cannabis) are more likely to use cannabis frequently — for pain, sleep, or other age-related complaints — rather than the other way around. This is known as reverse causality, and cross-sectional data cannot rule it out.
• Self-reported use. Participants told interviewers how often they used cannabis. Self-reports in federally administered surveys tend to underestimate use, and “frequent” in NHANES coding generally means daily or near-daily in the past 30 days. Occasional weekend use is not in the frequent bucket.
• No route-of-administration detail. The paper does not separate smoked flower from vaped concentrate from edibles. Combustion byproducts, oxidative stress, and heavy-metal exposure from contaminated product could each plausibly affect Klotho through pathways that have nothing to do with cannabinoids themselves. The companion lung-health research review discusses combustion-specific concerns.
• Potency and product era. Data spans 2007–2016, when average flower THC was lower and the legal market was smaller. It is not clear how results would replicate with today’s higher-potency products.
• Residual confounding. Frequent users may differ from never-users in diet, sleep, stress, income stability, and chronic disease burden in ways the model cannot fully capture. The high E-value raises the bar for an alternative explanation, but does not eliminate one.

The Wei 2025 replication

A few months earlier, Wei and Chen published a short report in Tobacco Induced Diseases using the same NHANES 2007–2016 window, with a slightly larger sample (6,601 adults aged 40–59) and a different modeling approach. They reported current marijuana use was associated with lower log-transformed α-Klotho (β = −0.084; 95% CI: −0.126 to −0.041) after adjusting for tobacco use and recent illicit drug use. The effect was larger in people who used both marijuana and tobacco (β = −0.112), and persisted in non-smokers (β = −0.087). The direction of effect matches Wang 2026, and the two papers together make it harder to dismiss the finding as a single-team artifact.

Replication matters. Two independent groups, working with overlapping but not identical samples and models, arriving at the same direction, adds weight to the signal. It still does not establish causation.

What this does — and does not — tell us

What the evidence supports right now:

• In middle-aged U.S. adults, frequent cannabis use is associated with modestly lower circulating Klotho.
• The association is dose-dependent and independent of tobacco.
• The signal is consistent across two independent NHANES analyses.

What the evidence does not yet support:

• That cannabis causes accelerated biological aging. The studies are cross-sectional.
• That the observed Klotho difference translates into measurable clinical outcomes — cardiovascular events, cognitive decline, mortality — at an individual level. That would require longitudinal follow-up the current data cannot provide.
• That occasional or moderate use carries the same signal. “Frequent” in NHANES typically means daily or near-daily.
• That any specific consumption method drives the effect. Flower, concentrates, edibles, and combustion were not separated.

The honest scientific answer is: this is an interesting, replicated, but early signal, and it deserves longitudinal follow-up before anyone changes clinical advice. Research indicates a biomarker association, not a proven aging pathway.

Practical takeaways for consumers

If you use cannabis, here is what a fair reading of the current data suggests, without catastrophizing and without dismissing:

1. Frequency is the variable that matters most in this dataset. The signal attached to frequent — daily or near-daily — use. Occasional use did not show the same effect. If you use less than a few times a week, this specific biomarker research is not describing your pattern.
2. Combustion is a separate, well-documented risk. Whether the Klotho signal is driven by cannabinoids, by smoke exposure, or by contaminants, smoke is its own established concern. Readers interested in reducing combustion exposure can compare consumption methods by bioavailability.
3. The loudest Klotho signals in the broader literature are lifestyle, not cannabis. Sleep quality, physical activity, dietary quality, and tobacco exposure all show larger associations with Klotho than the cannabis effect reported here. Fixing the basics likely matters more than any single cannabis decision.
4. If you are using frequently, consider periodic tolerance breaks. Independent of this study, structured breaks can help reset receptor sensitivity and give your body a baseline to compare against. Our tolerance break guide walks through evidence-informed approaches.
5. Pay attention to your own trajectory. For cardiovascular and metabolic context that intersects with Klotho biology, the heart-health review and the inflammation science article are relevant companions.
6. Match the product to the goal. Full-spectrum, terpene-aware sessions may matter more than raw THC numbers — the Entourage High family explains why synergy between cannabinoids and terpenes changes the experience, and the Relax High family covers myrcene-dominant profiles often used at higher frequencies. Understanding which profile you actually reach for can help you moderate intentionally.
7. Talk to a clinician if you have age-related risk factors. If you have cardiovascular, renal, or cognitive risk factors, this study is one more datapoint worth sharing with your doctor — not a reason to panic, but a reason for a grown-up conversation.

The one-line version: frequent use may be associated with modestly lower levels of an aging biomarker, the data is not conclusive, and the fundamentals of sleep, movement, and reducing combustion almost certainly matter more for your actual healthspan.

Sources

• Wang L, Ji Y, Wang T, Wang W, Zong G. “Association between cannabis consumption and serum Klotho levels in middle-aged U.S. adults: NHANES cross-sectional analysis.” Journal of Cannabis Research 8(1), 18 (2026). DOI: 10.1186/s42238-025-00380-x. PMCID: PMC12870139.
• Wei K, Chen X. “Current marijuana use is associated with lower circulating α-Klotho levels in US adults even after adjusting for tobacco use: A national cross-sectional analysis of NHANES.” Tobacco Induced Diseases 23 (July 2025):104. DOI: 10.18332/tid/208001. PMCID: PMC12292049.
• Huang M, Huang G, Wu C, Zhu L, Pei B, Wang H, et al. “Klotho levels and biological age acceleration: Insights from a diverse cohort of middle-aged and elderly individuals.” PLoS One 21(3), e0343429 (2026). DOI: 10.1371/journal.pone.0343429.
• Yao Y, Long Y, Du FW, Zhao Y, Luo XB. “Association between serum cotinine and α-Klotho levels among adults: Findings from NHANES 2007–2016.” Tobacco Induced Diseases 20(June):57 (2022). DOI: 10.18332/tid/144622.
• Kuro-o M. “The Klotho proteins in health and disease.” Nature Reviews Nephrology 15(1): 27–44 (2019). DOI: 10.1038/s41581-018-0078-3.
• Kurosu H, Yamamoto M, Clark JD, et al. “Suppression of aging in mice by the hormone Klotho.” Science 309(5742): 1829–1833 (2005). DOI: 10.1126/science.1112766.